Clinical Trials Logo

Perfusion Imaging clinical trials

View clinical trials related to Perfusion Imaging.

Filter by:
  • None
  • Page 1

NCT ID: NCT05311605 Recruiting - Stroke Clinical Trials

REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion

RESTORE
Start date: February 23, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of the study was to establish a clinical and advanced imaging database of acute ischemic stroke patients treated with mechanical thrombectomy due to large vessel occlusion of anterior circulation within 24 hours from stroke onset in China, and to investigate the predictors and potential mechanisms of futile recanalization after mechanical thrombectomy.

NCT ID: NCT04181281 Not yet recruiting - Kidney Diseases Clinical Trials

Validation of Renal Perfusion CEUS Against MRI, and Its Application in Acute Kidney Injury

Start date: April 2021
Phase:
Study type: Observational

The purposes of this study is 1. To establish the validity of CEUS to measure renal perfusion by comparing it against ASL-MRI in young and older healthy volunteers, and generate a normative dataset of CEUS measures of renal perfusion. 2. Establish proof of principle for the use of CEUS to measure renal perfusion in the acute phase of AKI, demonstrating its feasibility and potential clinical utility. We will do this by performing daily CEUS measurements for up to five days in a cohort of people with AKI stage 3, commencing as close to onset. of AKI as possible, correlating with clinical data and following outcomes until 90 days.

NCT ID: NCT01277055 Recruiting - Myocardial Ischemia Clinical Trials

MRI Perfusion Imaging at 3Tx Compared to Invasive FFR Measurements

Vision MRT
Start date: January 2011
Phase: N/A
Study type: Observational

Coronary artery disease (CAD) has a great significance concerning prevalence and mortality in the western world. It is usually diagnosed by catheterization and coronary arteries are visually assessed by the examiner. Thus having a great spectrum of interobserver differences, especially when it comes to intermediate lesions. The gold standard to assess the haemodynamic significance is the measurement of the myocardial fractional flow reserve (FFR). The FAME-study (Tonino, De Bruyne et al. 2009) was able o show that additional FFR- measurements in patients with intermediate lesions could significantly reduce stent implementation and consequently mortality. However this method is not used in daily routine and is available only in a fraction of catheter labs worldwide. Taking this into account decision finding especially in intermediate lesions remains difficult. One major step to simplify the invasive approach concerning intermediate lesions would be to establish a non-invasive procedures which localizes the coronary vessel to intervene ahead catheterization. Do to steady technical development cardiac MRI has become a powerful tool which is able to determine myocardial vitality, perfusion and function. In particular the new generation of 3 Tesla multi transmit MR with its higher field strength and better spatial resolution seems to be able to show first pass myocardial perfusion more precise. With this new technology prefixed to cardiac catheterization clinical relevant information can be made accessible and thus reduce the number of unnecessary implemented stents.